Amedisys Inc. (NASDAQ:AMED) is seeing continued growth in the home health segment amediments, amedis Inc. (NASDAQ:AMED) is seeing continued growth.
On Wednesday, Amedisys released its second quarter financial results for 2025, forecasting the expected impact if the proposed home health payment rules are finalized. The company has chosen to hold an accompanying conference call.
Amedisys' service lines include home hygiene, hospice and palliative care services. The company provides care in 38 states and Washington, DC, employs 19,000 people and provides care to more than 499,000 patients per year. It owns and operates 347 Medicare-certified Home Medical Centers.
In the second quarter, Amedisys' Home Health Segment reported net service revenue of $396.2 million, up from $377.4 million in the same quarter in 2024.
Amedisys has seen an increase in overall revenue. The company generated net service revenue of $621.9 million in the second quarter, compared to $591.2 million in 2024.
In its SEC Form 10-Q filing, Amedisys also addressed the 2026 home health proposal payment rules. Last month, the Centers for Medicare and Medicaid Services (CMS) in the US released an annual proposal that includes a 6.4% overall cut to home health payments.
“Based on an analysis of the proposed rules, we expect our impact to be in line with a 6.4% decline,” the company wrote. “Amedisys is partnering with industry advocates, lobbying companies and others to share comments with the CMS on the proposed rules.”
Despite strong quarterly performance, the UnitedHealth Group lawsuit remains on the company.
“We are holding AMED as we continue to await the outcome of the lawsuit filed by DOJ trying to block the sale to UNH,” Jefferies wrote in an analyst's note. “We believe that the sale package is positive (Brightspring Health Services (NASDAQ: BTSG) and Pennant Group (NASDAQ: PNTG)) are two viable buyers that will satisfy the DOJ.”
In 2023, UnitedHealth Group offered a full speed of $3.3 billion to buy Amedisys. The following year, DOJ sues to prevent the contract from being made. DOJ argued that the acquisition would have a negative impact on patients, payers and home health workers.
In May, Amedisys signed an agreement to sell its home hygiene and hospice care centre to Pennant and Brightspring affiliates.
On August 18th, DOJ, Amedisys and UnitedHealth Group will be mediated.
As last month, UnitedHealth Group expressed confidence in the transaction with documents that were missed in statistics.
“We remain optimistic about completing the proposed merger and Amedisys,” the document read. “Amejiji's commitment to domestic quality and care innovation, and patient culture combined with Optum's deep value-based care expertise, could promote meaningful improvements in health outcomes and experiences for more patients, leading to the continued growth of both organizations.”
